NCT06875193

DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes

Key Finding of DM Treatment with Combination, a MuLticenter, Randomized, Parallel, Gathering Information of Phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone Add-on to Metformin and DPP-4 Inhibitor in Patients with Type 2 Diabetes

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 196 (estimated)
• Sponsor: Dong Wha Pharmaceutical Co. Ltd. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4 inhibitor in Patients with Type 2 Diabetes Who Have Inadequate Glycaemic Control on a Background Combination of Metformin and DPP-4 inhibitor(KLIMT Study)

Detailed description

This is a Phase 4, multicenter, randomized, open-label, parallel clinical trial

Conditions

• Type2diabetes

Interventions

Type	Name	Description
DRUG	DW6012(Dasidiem tab. 10/100mg)	Once a day, Oral administration

Timeline

• Start date: 2024-05-28
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-03-13
• Last updated: 2025-03-17

Locations

1 site across 1 country: South Korea